Sabby Management’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-4,497
Closed -$69.7K – 27
2026
Q2
$69.7K Sell
4,497
-17,529
-80% -$194K 0.06% 21
2026
Q1
$142K Buy
22,026
+1,863
+9% +$17.6K 0.32% 19
2025
Q4
$214K Sell
20,163
-1,837
-8% -$30.5K 0.31% 23
2025
Q3
$482K Buy
+22,000
New +$530K 0.56% 16
2024
Q3
– Sell
-1,536
Closed -$81.6K – 53
2024
Q2
$81.6K Sell
1,536
-273
-15% -$15.6K 0.05% 29
2024
Q1
$132K Sell
1,809
-751
-29% -$55.2K 0.08% 28
2023
Q4
$213K Buy
+2,560
New +$248K 0.21% 22
2022
Q4
– Sell
-76
Closed -$101K – 118
2022
Q3
$101K Buy
+76
New +$141K 0.13% 80

Other funds holding MTRI

Sabby Management's MTRI Position: Q3 2026 in Review

Sabby Management sold out of Mentari Therapeutics, Inc. Common Stock (MTRI) in Q3 2026, closing a stake of 4,497 shares — an estimated $69.7K sold.

Sabby Management first reported a position in MTRI in Q3 2022 and held it in 8 quarters. The position peaked at $482K in Q3 2025. 16 funds tracked by Wall St. Rank hold MTRI as of Q3 2026.

  • Sabby Management reported no remaining Mentari Therapeutics, Inc. Common Stock position as of Q3 2026 after selling out during the quarter.
  • Sabby Management sold 4,497 Mentari Therapeutics, Inc. Common Stock shares in Q3 2026, an estimated $69.7K.
  • Sabby Management first reported a position in Mentari Therapeutics, Inc. Common Stock in Q3 2022 and held it in 8 quarters.
  • Sabby Management's Mentari Therapeutics, Inc. Common Stock position peaked at $482K in Q3 2025.
  • 16 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q3 2026.

Based on Sabby Management's 13F filing for Q3 2026, filed 13 Nov 2026.